265 related articles for article (PubMed ID: 15956627)
21. The CREATE Act: increasing costs associated with the biotech industry?
Mills AE; Chen DT; Gillon JJ; Tereskerz PM
Nat Biotechnol; 2006 Jul; 24(7):785-6. PubMed ID: 16841059
[TBL] [Abstract][Full Text] [Related]
22. Amgen cholesterol antibody feud could kill key IP rule.
Ratner M
Nat Biotechnol; 2017 Dec; 35(12):1118-1119. PubMed ID: 29220019
[No Abstract] [Full Text] [Related]
23. Ordering life: law and the normalization of biotechnology.
Jasanoff S
Not Polit; 2001; 17(62):34-50. PubMed ID: 15468485
[No Abstract] [Full Text] [Related]
24. Bungled law threatens Italian tech transfer.
Meldolesi A
Nat Biotechnol; 2001 Nov; 19(11):996-7. PubMed ID: 11689829
[No Abstract] [Full Text] [Related]
25. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
26. Data-sharing and data-withholding in genetics and the life sciences: results of a national survey of technology transfer officers.
Campbell EG; Bendavid E
J Health Care Law Policy; 2003; 6(2):241-55. PubMed ID: 15017960
[No Abstract] [Full Text] [Related]
27. Trust, patents and public perceptions: the governance of controversial biotechnology research.
Caulfield T; Einsiedel E; Merz JF; Nicol D
Nat Biotechnol; 2006 Nov; 24(11):1352-4. PubMed ID: 17093477
[TBL] [Abstract][Full Text] [Related]
28. "Ganske" threatens biotechnology patents worldwide.
Glaser V
Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
[No Abstract] [Full Text] [Related]
29. Companies balk at California's patent rules for stem cell research.
Keim B
Nat Med; 2007 Jan; 13(1):6. PubMed ID: 17206112
[No Abstract] [Full Text] [Related]
30. Biotechnology: a challenge for Hippocrates.
Huynen S
Auckl Univ Law Rev; 1991; 6(4):534-51. PubMed ID: 16127862
[No Abstract] [Full Text] [Related]
31. Patent and license pearls and pitfalls for taking an idea to the marketplace.
Mukharji I
J Investig Med; 2011 Jun; 59(5):758-61. PubMed ID: 21441827
[TBL] [Abstract][Full Text] [Related]
32. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape.
Lu DL; Kowalski TJ; Jarecki-Black J
Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040
[No Abstract] [Full Text] [Related]
33. Hatch-waxman changes debated.
Chahine K
Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
[No Abstract] [Full Text] [Related]
34. Patents and innovation in cancer therapeutics: lessons from CellPro.
Bar-Shalom A; Cook-Deegan R
Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643
[TBL] [Abstract][Full Text] [Related]
35. Lessons from Bayh-Dole.
Sampat BN
Nature; 2010 Dec; 468(7325):755-6. PubMed ID: 21150971
[No Abstract] [Full Text] [Related]
36. Lecture: patents, product exclusivity, and information dissemination: how law directs biopharmaceutical research and development.
Eisenberg RS
Fordham Law Rev; 2003 Dec; 72(3):477-91. PubMed ID: 14968794
[No Abstract] [Full Text] [Related]
37. Patent fight sparks biological warfare in the drug industry.
Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
[No Abstract] [Full Text] [Related]
38. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
Hazuka CD
Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
[No Abstract] [Full Text] [Related]
39. From bench to market: life science patents in Europe.
Rutz B
Biotechnol J; 2012 Feb; 7(2):171-5. PubMed ID: 22307913
[No Abstract] [Full Text] [Related]
40. Universities struggle to make patents pay.
Ledford H
Nature; 2013 Sep; 501(7468):471-2. PubMed ID: 24067689
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
